Graph-based algorithms for the efficient solution of a class of optimization problems

In this paper, we address a class of specially structured problems that include speed planning, for mobile robots and robotic manipulators, and dynamic programming. We develop two new numerical procedures, that apply to the general case and to the linear subcase. With numerical experiments, we show that the proposed algorithms outperform generic commercial solvers.Comment: 27 pages, 9 figures, 1 tabl

Project controlling in mega events: the Expo 2015 case

Although Universal Expositions are an incredible catalyst for the development of hosting cities, they have to face projects’ common problems as over-budgets and delays. This last issue is critic since mega events have to respect a mandatory deadline and any delay could cause critical project scope reduction. It is thus fundamental to control efficiently and effectively their progress to obtain the best performances. Despite “project controlling” field is well-documented concerning mega-projects, there is a gap for mega events. In addition, literature focuses on strategic elements without providing operative methods to control the execution phase. This paper fi lls this gap highlighting how mega-events can be considered as “mega-programmes”, suggesting supervision through a project envelope to avoid forecasting problems and proposing a gradual control according to project statuses. These results provide a model to monitor Milan Expo 2015 execution phase, guaranteeing that all projects involved end within deadlines

immunizing against breast cancer a new swing for an old sword

Summary Therapeutic potential of vaccination has been explored in many clinical trials involving patients with breast cancer. A large variety of cancer immunogens have been tested. The majority of clinical vaccination studies have been carried out in patients with metastatic breast cancer, characterized by extremely aggressive malignant tumors, resistant to all standard cytotoxic treatments and with longest-lasting disease. With active specific immunotherapy, tumor-associated antigens coupled to appropriate adjuvant can elicit a powerful antitumor responses. The potential advantages of therapeutic cancer vaccines are that they can augment an established immunogenic response to the tumor (which is generally weak in breast cancer), they target specific tumor antigens (although there are few), they are potentially non-toxic, they can be combined with conventional therapies and/or other immunotherapies, and they elicit immunologic memory to prevent recurrence of the tumor. It is unclear whether therapeutic vaccines for cancer prolong survival. Data of clinical activity have been observed by using vaccines targeting HER-2/neu protein, human telomerase reverse transcriptase, carcinoembryonic antigen (CEA), and carbohydrate antigen given after stem cell rescue. A better understanding of the relation between innate and adaptive immune responses, and of the immune escape mechanisms employed by tumor cells, the discovery of mechanisms underlying immunological tolerance, and acknowledgment of the importance of both cell-mediated and humoral adaptive immunity for the control of tumour growth are necessary for leading to a more comprehensive immunotherapeutic approach in breast cancer